Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
10 December, 2018 01:01 IST
Panacea Biotec receives EIR for oncology manufacturing facility
Source: IRIS | 12 Mar, 2018, 10.40AM
Comments  |  Post Comment

Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration ('USFDA') indicating the formal closure of the Inspection conducted by USFDA, at its Pharmaceutical Formulation Facility for Oncology Parenteral and Oral Solids Dosage at Malpur, Baddi, District Solan, Himachal Pradesh, India.

Shares of the company gained Rs 9.7, or 3.45%, to trade at  Rs 290.75.  The total volume of shares traded  was  12,527 at the BSE (10.29 a.m., Monday).



Panacea Biotec Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
HCL Tech to acquire select IBM Software products for USD 1.8 bn - 07-Dec-2018 10:08
Wipro, Alfresco expand pact to offer digital transformation capabilities - 07-Dec-2018 09:59
Indian Hume Pipe Co receives contract worth Rs 2.04 bn - 06-Dec-2018 09:50
Infosys inaugurates technology and innovation hub in Hartford - 06-Dec-2018 09:46
USFDA completes inspection of Lupin's Mandideep location - 05-Dec-2018 15:31
NTPC wins 85MW solar projects in UPNEDA's solar tender - 05-Dec-2018 15:03
Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets - 05-Dec-2018 13:05
Kridhan Infra's associate Co bags orders worth Rs 1.05 bn - 05-Dec-2018 10:06
Lupin launches generic Silodosin capsules in United States - 05-Dec-2018 09:54
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer